New drug tested in kidney patients: how does it behave?
NCT ID NCT07217886
First seen Jun 27, 2026 · Last updated Jul 14, 2026 · Updated 2 times
Summary
This study looks at how the body handles a new drug called S-892216 in people with mild, moderate, or severe kidney problems, including those on dialysis, compared to people with healthy kidneys. About 40 adults will take a single dose of the drug, and researchers will measure its levels in the blood and dialysis fluid. The goal is to understand how kidney function affects the drug, not to treat any condition.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Alliance for Multispecialty Research (AMR)-Knoxville
Knoxville, Tennessee, 37920, United States
-
Genesis Clinical Research
Tampa, Florida, 33603, United States
-
Global Clinical Professionals (GCP) LLC
St. Petersburg, Florida, 33705, United States
-
Orlando Clicinal Research Center
Orlando, Florida, 32809, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Aging kidneys under the microscope: could a simple test predict failure?
- Could your gut bacteria hold the key to protecting your kidneys?
- Food as medicine: could cooking classes slow kidney disease?
- Can a damaged kidney change how antibiotics work?
- Could a phone app be the key to managing kidney disease?
- A new pill aims to slow kidney failure and save lives